VYNDAQEL (tafamidis) Capsules

VYNDAQEL is a prescription medicine used to treat Liver Diseases. FDA approved tafamidis (brand name VYNDAQEL) is not (yet) registered or available in India but on request Indian patient can buy VYNDAQEL at the lowest price.

VYNDAQEL (tafamidis) Capsules Price In Delhi India Ahmedabad Bengaluru Chennai Kolkata Mumbai
VYNDAQEL (tafamidis) Capsules

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Indian Patient Enquiry under NPP.

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

VYNDAQEL (tafamidis) Capsules

Tafamidis is used to treat cardiomyopathy (enlarged and thickened heart muscle) of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce death and hospitalization related to heart problems.

VYNDAQEL and VYNDAMAX are transthyretin stabilizers indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.

Tafamidis is used to delay nerve damage in adults who have transthyretin amyloidosis with polyneuropathy, or heart disease in adults who have transthyretin amyloidosis with cardiomyopathy. Active ingredient: tafamidis meglumine. Inactive ingredients: ammonium hydroxide 28%, brilliant blue FCF, carmine, ethyl alcohol, gelatin, glycerin, iron oxide (yellow), isopropyl alcohol, polyethylene glycol 400, polysorbate 80, polyvinyl acetate phthalate, propylene glycol, purified water, sorbitan monooleate, sorbitol, and titanium dioxide.

Drug Brand Name: VYNDAQEL (tafamidis meglumine) capsules, for oral administration
Strength: Capsules: Tafamidis meglumine 20 mg and tafamidis 61 mg
Current Indication: Treat Liver Diseases
Marketed By: Pfizer Inc.
Approval Date: : 2019

Capsules: Tafamidis meglumine 20 mg and tafamidis 61 mg

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.